Abstract:Abstract Unlimited replicative capacity is a key hallmark of cancer that requires the abrogation of telomere attrition due to the end-replication problem. The vast majority of tumors maintain telomere lengths by expressing the enzyme telomerase; however, a subset utilizes a cancer-specific, telomerase-independent telomere maintenance mechanism, termed Alternative Lengthening of Telomeres (ALT). We recently uncovered a strong correlation between ALT and recurrent cancer-associated somatic inactivating mutations in the ATRX and DAXX genes. The ATRX and DAXX proteins form a chromatin remodeling complex with histone chaperone activity, targeting incorporation of the histone variant H3.3 to G-rich repetitive regions of the genome, including the telomeres, which are known to normally be maintained in a repressed heterochromatic state. Here, we have developed an isogenic cell line pair derived from first generation telomerase knock-out (KO) mouse embryonic fibroblasts. Compared to early-passage telomerase KO cells and late passage WT control cells, late-passage telomerase KO cells spontaneously developed the ALT phenotype. These ALT(+) cells display increased DNA damage, as observed by dramatically increased accumulation of γH2AX foci. We plan to use this unique cell line to identify drugs exhibiting selective toxicity for ALT(+) cells. Preliminary results indicate that ALT(+) late-passage telomerase KO cells exhibit an increased sensitivity to the DNA-PK inhibitor NU7441 compared to the isogenic early-passage ALT(-) telomerase KO cells. The identification of bona fide ALT-specific drugs will pave the way for the development of new targeted treatments for the significant number of cancers that harbor this unique molecular phenotype. Citation Format: Christopher M. Heaphy, Michael C. Haffner, Alan K. Meeker. A novel cell line model of the alternative lengthening of telomeres (ALT) telomere maintenance mechanism. [abstract]. In: Proceedings of the AACR Special Conference on Chromatin and Epigenetics in Cancer; Jun 19-22, 2013; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2013;73(13 Suppl):Abstract nr A06.

Histone demethylase KDM2A is a selective vulnerability of cancers relying on alternative telomere maintenance

Abstract A06: A novel cell line model of the alternative lengthening of telomeres (ALT) telomere maintenance mechanism

RAD51AP1 Is an Essential Mediator of Alternative Lengthening of Telomeres

The Single-Stranded DNA-Binding Factor SUB1/PC4 Alleviates Replication Stress at Telomeres and is a Vulnerability of ALT Cancer Cells

Alternative lengthening of telomeres: from molecular mechanisms to therapeutic outlooks

Alternative Lengthening of Telomeres and Mediated Telomere Synthesis

Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway

ATRX Loss Induces Telomere Dysfunction and Necessitates Induction of Alternative Lengthening of Telomeres During Human Cell Immortalization

Histone-methyltransferase KMT2D deficiency impairs the Fanconi anemia/BRCA pathway upon glycolytic inhibition in squamous cell carcinoma

Alternative Lengthening of Telomeres: DNA Repair Pathways Converge

Alternative Lengthening of Telomeres Mediated by Mitotic DNA Synthesis Engages Break-Induced Replication Processes

LAP2α orchestrates alternative lengthening of telomeres suppression through telomeric heterochromatin regulation with HDAC1: unveiling a potential therapeutic target

Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT)

Alternative Lengthening Of Telomeres In Htert-Inhibited Laryngeal Cancer Cells

SUMO Promotes DNA Repair Protein Collaboration to Support Alterative Telomere Lengthening in the Absence of PML

Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function

Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX

Reprogramming Chromosome Ends by Functional Histone Acetylation

Selective Elimination of Osteosarcoma Cell Lines with Short Telomeres by Ataxia Telangiectasia and Rad3-Related Inhibitors